BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy

Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.

Affiliations

¹ Foundation Medicine, Inc, Cambridge, MA. Electronic address: egornstein@foundationmedicine.com.
² Northwest Medical Specialties, Puyallup, WA.
³ Foundation Medicine, Inc, Cambridge, MA.
⁴ Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

PMID: 29325860
DOI: 10.1016/j.clbc.2017.12.010

No abstract available

Keywords: BRCA reversion; Circulating tumor DNA; Metastatic breast cancer; PARP inhibitor; ctDNA.

Publication types

Case Reports

MeSH terms

BRCA2 Protein / genetics*
Breast Neoplasms / blood
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics
Breast Neoplasms / pathology
DNA Mutational Analysis
Disease Progression
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / genetics
Fatal Outcome
Female
Germ-Line Mutation / drug effects
Humans
Liquid Biopsy
Liver / pathology
Liver Neoplasms / blood
Liver Neoplasms / drug therapy*
Liver Neoplasms / pathology
Liver Neoplasms / secondary
Loss of Heterozygosity
Middle Aged
Phthalazines / pharmacology*
Phthalazines / therapeutic use
Piperazines / pharmacology*
Piperazines / therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology*
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Receptors, Estrogen / metabolism

Substances

BRCA2 Protein
BRCA2 protein, human
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
Receptors, Estrogen
olaparib